Future developments

  • A further reduction in smoking prevalence in all groups may be achieved by government campaigns with the longer-term goal of reducing lung cancer incidence. However, this will require intensification and further funding of smoking-cessation programmes.
  • Genetic profiling of lung cancer may become routinely available or be encompassed in clinical trials, and will enable therapy to be personalised using targeted agents according to the genetic profile of the tumour.
  • Standardised and universal data collection for patients with lung cancer across Europe must be a priority.
  • Positron emission tomography-computed tomography (PET-CT), endobronchial ultrasound (EBUS) and endoscopic ultrasound (EUS) will play a prominent role in diagnosing and staging lung cancer.
  • Lung-sparing radiotherapy techniques will become more widely available.
  • The clinical effectiveness and cost-effectiveness of lung cancer screening with low-dose computed tomography (CT) will be clarified, as will patient selection.
  • There will be a focus on quality of life of patients with advanced lung cancer as well as survival.
  • Patients will have improved access to palliative care resources.

See the entire Lung Cancer Chapter